A randomized, double-blind, crossover trial of modafinil on mood

Journal of Clinical Psychopharmacology

Volumn 27, Issue 1, 2007, Pages 76-79

  Taneja, Indu ^a   Haman, Kirsten ^a   Shelton, Richard C ^a   Robertson, David ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MODAFINIL; PLACEBO;

ADULT; AFFECT; ANXIETY; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; MOOD; NORMAL HUMAN; PRIORITY JOURNAL; PSYCHOLOGIC ASSESSMENT;

ADMINISTRATION, ORAL; ADULT; AFFECT; BENZHYDRYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; MALE; REFERENCE VALUES;

EID: 33846191926     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/jcp.0b013e31802eb7ea     Document Type: Article

References (25)

1. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group. Ann Neurol. 1998;43(1):88-97.
2. Pigeau R, Naitoh P, Buguet A, et al. Modafinil, D-amphetamine and placebo during 64 hours of sustained mental work. I. Effects on mood, fatigue, cognitive performance and body temperature. J Sleep Res. 1995;4(4):212-228.
3. MacDonald JR, Hill JD, Tarnopolsky MA. Modafinil reduces excessive somnolence and enhances mood in patients with myotonic dystrophy. Neurology. 2002;59(12):1876-1880.
4. Becker PM, Schwartz JR, Feldman NT, et al. Effect of modafinil on fatigue, mood, and health-related quality of life in patients with narcolepsy. Psychopharmacology (Berl). 2004;171(2):133-139.
5. Turner DC, Robbins TW, Clark L, et al. Cognitive enhancing effects of modafinil in healthy volunteers. Psychopharmacology. 2003;165(3):260-269.
6. Randall DC, Shneerson JM, Plaha KK, et al. Modafinil affects mood, but not cognitive function, in healthy young volunteers. Hum Psychopharmacol. 2003;18(3):163-173.
7. DeBattista C, Lembke A, Solvason HB, et al. A prospective trial of modafinil as an adjunctive treatment of major depression. J Clin Psychopharmacol. 2004;24(1):87-90.
8. DeBattista C, Doghramji K, Menza MA, et al. Adjunct modafinil for the short-term treatment of fatigue and sleepiness in patients with major depressive disorder: a preliminary double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64(9):1057-1064.
9. Swanson JM, Greenhill LL, Lopez FA, et al. Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. J Clin Psychiatry. 2006;67(1):137-147.
10. Watson D, Clark LA, McIntyre CW, et al. Affect, personality, and social activity. J Pers Soc Psychol. 1992;63(6):1011-1025.
11. Crawford JR, Henry JD. The Positive and Negative Affect Schedule (PANAS): construct validity, measurement properties and normative data in a large non-clinical sample. Br J Clin Psychol. 2004;43(pt 3):245-265.
12. Taneja I, Diedrich A, Black BK, et al. Modafinil elicits sympathomedullary activation. Hypertension. 2005;45(4):612-618.
13. Carey RM. Theodore Cooper Lecture: renal dopamine system: paracrine regulator of sodium homeostasis and blood pressure. Hypertension. 2001;38(3):297-302.
14. Wong YN, Simcoe D, Hartman LN, et al. A double-blind, placebo-controlled, ascending-dose evaluation of the pharmacokinetics and tolerability of modafinil tablets in healthy male volunteers. J Clin Pharmacol. 1999;39(1):30-40.
15. Katz IR, Morales K, Datto C, et al. Probing for affective side effects of drugs used in geriatric practice: use of daily diaries to test for effects of metoclopramide and naproxen. Neuropsychopharmacology. 2005;30(8):1568-1575.
16. Hopko DR, Armento ME, Cantu MS, et al. The use of daily diaries to assess the relations among mood state, overt behavior, and reward value of activities. Behav Res Ther. 2003;41(10):1137-1148.
17. Ranjan S, Chandra PS. Modafinil-induced irritability and aggression? A report of 2 bipolar patients. J Clin Psychopharmacol. 2005;25(6):628-629.
18. Taneja I, Diedrich A, Black B, et al. Sympathetic cardiovascular activation by modafinil. Hypertension. 2004;44(4):523.
19. Taneja I, Bruehl S, Robertson D. Effect of modafinil on acute pain: a randomised double-blind crossover study. J Clin Pharmacol. 2004;44:441-443.
20. Hariri AR, Mattay VS, Tessitore A, et al. Dextroamphetamine modulates the response of the human amygdala. Neuropsychopharmacology. 2002;27(6):1036-1040.
21. London ED, Simon SL, Berman SM, et al. Mood disturbances and regional cerebral metabolic abnormalities in recently abstinent methamphetamine abusers. Arch Gen Psychiatry. 2004;61(1):73-84.
22. Willner P. Dopaminergic mechanisms in depression and mania. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. 921. New York: Raven Press; 1995:32.
23. Tanganelli S, Perez de la Mora M, Ferraro L, et al. Modafinil and cortical γ-aminobutyric acid outflow modulation by 5-hydroxytryptamine neurotoxins. Eur J Pharmacol. 1995;273:63-71.
24. Ferraro L, Fuxe K, Tanganelli S, et al. Amplification of cortical serotonin release: a further neurochemical action of the vigilance-promoting drug modafinil. Neuropharmacology. 2000;39:1974-1983.
25. Ferraro L, Tanganelli S, O'Connor WT, et al. The vigilance promoting drug modafinil increases dopamine release in the rat nucleus accumbens via the involvement of a local GABAergic mechanism. Eur J Pharmacol. 1996;306:33-39.